Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC

About this update from Agenus Inc.

[{"type":"list","items":[{"val":[{"type":"text","content":"Deep and durable responses observed in a heavily pretreated, historically immunotherapy-resistant population","length":108,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Findings reinforce the broad, pan-tumor activity of BOT+BAL across immunologically "cold" cancers","length":107,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":215,"olType":false},{"type":"text","content":"LEXINGTON, Mass., December 23, 2025--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of clinical results from the ovarian cancer cohort of its Phase 1b C-800-01 trial evaluating botensilimab plus balstilimab (BOT+BAL) in The Journal for ImmunoTherapy of Cancer (JITC).","length":337,"tagName":"p"},{"type":"text","content":"The peer-reviewed manuscript titled, "Botensilimab (Fc-enhanced anti–CTLA-4 antibody) plus balstilimab (anti–PD-1 antibody) in patients with treatment-refractory ovarian cancer," is available online here.i","length":215,"tagName":"p"},{"type":"text","content":"In this heavily pretreated population, BOT+BAL demonstrated clinically meaningful activity and durable benefit in women with treatment-refractory ovarian cancer, a population with few remaining options. The combination achieved a 23% overall response rate and 31% clinical benefit rate, including durable responses with a median duration of 9.7 months. Median overall survival reached 14.8 months, with an estimated of 75% of patients alive at 12 months.","length":454,"tagName":"p"},{"type":"text","content":"These findings build on results from the broader C-800-01 dataset presented at ESMO 2025, where BOT+BAL showed activity across multiple refractory solid tumors. Collectively, these data reinforce the potential of BOT+BAL to generate meaningful immune responses in cancers historically considered unresponsive to immunotherapy.","length":326,"tagName":"p"},{"type":"text","content":"High Unmet Need in Treatment-Refractory Ovarian Cancer","length":54,"tagName":"p"},{"type":"text","content":"Ovarian cancer causes approximately 13,000 deaths annually in the U.S. and 200,000 globallyii,iii, and outcomes are particularly poor once tumors become platinum-resistant or platinum-refractory. Therapy with first-generation checkpoint inhibi...

More updates from Agenus Inc.